Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2000-2-29
pubmed:abstractText
To determine the safety and tolerability of adenovirus-mediated p53 (Adp53) gene transfer in sequence with cisplatin when given by intratumor injection in patients with non-small-cell lung cancer (NSCLC).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
609-22
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10653876-Adenoviruses, Human, pubmed-meshheading:10653876-Adult, pubmed-meshheading:10653876-Aged, pubmed-meshheading:10653876-Antibodies, Viral, pubmed-meshheading:10653876-Antineoplastic Agents, pubmed-meshheading:10653876-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:10653876-Cisplatin, pubmed-meshheading:10653876-Combined Modality Therapy, pubmed-meshheading:10653876-DNA, Neoplasm, pubmed-meshheading:10653876-DNA Mutational Analysis, pubmed-meshheading:10653876-Female, pubmed-meshheading:10653876-Gene Transfer Techniques, pubmed-meshheading:10653876-Genes, p53, pubmed-meshheading:10653876-Genetic Vectors, pubmed-meshheading:10653876-Humans, pubmed-meshheading:10653876-In Situ Nick-End Labeling, pubmed-meshheading:10653876-Injections, Intralesional, pubmed-meshheading:10653876-Lung Neoplasms, pubmed-meshheading:10653876-Male, pubmed-meshheading:10653876-Middle Aged, pubmed-meshheading:10653876-Organ Specificity, pubmed-meshheading:10653876-Staining and Labeling
pubmed:year
2000
pubmed:articleTitle
Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.
pubmed:affiliation
US Oncology, Baylor University Medical Center, Dallas, TX, USA. j.nemunaitis@usoncology.com
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I